The study presents valuable insights into indication-specific dosing strategies for non-oncology monoclonal antibodies, but a few areas could benefit from further clarification. While the study highlights differences in dosing approaches, could the authors elaborate on how variability in pharmacokinetics across indications was accounted for? Were population-based PK models or real-world data considered to support dose adjustments? Moreover, the study discusses potential benefits of indication-specific dosing, but were any cost-effectiveness or patient outcome comparisons made?
